Form 4: Roivant CFO Richard Pulik Receives Equity Award

Roivant Sciences CFO Richard Pulik was granted 60,644 restricted stock units and 84,026 stock options as part of a compensation package.

Summary

• CFO Richard Pulik received an award of 60,644 restricted stock units (RSUs).
• CFO Richard Pulik received an award of 84,026 stock options with an exercise price of $29.08.
• The vesting commencement date for both awards is April 20, 2026.
• Following these transactions, the reporting person holds 297,511 common shares directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine disclosure of executive compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of executive interests with long-term shareholder value through equity-based compensation.
• Retention of key financial leadership through multi-year vesting schedules.

Negatives

• Potential for future shareholder dilution upon the exercise of stock options and vesting of RSUs.

Risks

• Continuous service requirements for vesting may impact executive retention if not met.
• Market price volatility could affect the ultimate value realized by the executive from these equity grants.

Future Outlook

The equity awards are subject to multi-year vesting schedules, indicating a long-term commitment to the company's performance.

Management Comments

• The awards are subject to the reporting person's continuous service through the applicable vesting dates.

Industry Context

StockSavvy.ai notes that equity-based compensation for C-suite executives is standard practice in the biotechnology sector to align management incentives with long-term clinical and commercial milestones.

Comparison to Industry Standards

• The use of a 4-year vesting schedule is consistent with standard corporate governance practices for executive equity grants in the U.S. biotech industry.
• The inclusion of both RSUs and stock options is a common compensation structure for executives at mid-to-large cap pharmaceutical companies.

Stakeholder Impact

• Shareholders may experience minor dilution upon the eventual exercise or vesting of these equity instruments.

Next Steps

• Vesting of 25% of RSUs on April 20, 2027.
• Vesting of 25% of stock options on April 20, 2027.

Key Dates

Keywords

Roivant Sciences, ROIV, Form 4, Insider Trading, Executive Compensation, CFO